TST conversions and systemic interferon-gamma increase after methotrexate introduction in psoriasis patients.

BACKGROUND: Tuberculosis screening in psoriasis patients is complex due to the immunological alterations associated with psoriasis, the presence of comorbidities, and the effect of immunosuppressive treatment. However, it is not established whether the results of screening tests are affected by these factors in psoriasis patients.
OBJECTIVES: To determine whether there is a change in the results of the tuberculin skin test (TST) or the interferon-gamma release assay (IGRA) in psoriasis patients living in tuberculosis (TB)-endemic area after 12 weeks of methotrexate (MTX) treatment and to investigate the association of the test results with clinical and inflammatory markers.
METHODS: Forty-five patients were selected for a prospective single-arm self-controlled study and followed for at least 18 months. The TST, IGRA, Psoriasis Area and Severity Index (PASI), and inflammatory factors (erythrocyte sedimentation rate (ESR), C-reactive protein, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha levels), were determined before and after 12 weeks of oral 15 mg per week MTX administration and compared. The associations between the IGRA and TST results were verified before and after treatment according to inflammatory factors and clinical characteristics (age, blood glucose, weight, body mass index, disease duration, and PASI).
RESULTS: We collected data on 25 patients who completed the full course of therapy and the follow-up. None of the patients developed TB. TST positivity was significantly elevated at week 12 (25% baseline vs 44% at week 12, P < 0.037). Three IGRAs followed the TST conversions. There was no difference between TST and IGRA pre- or posttreatment. Serum IFN-γ increased significantly in week 12 (15.95 pg/ml baseline vs 18.82 pg/ml at week 12, P < 0.005) and tended to be higher among TST-positive patients (P = 0.072). The baseline IGRA was associated with a higher ESR (P = 0.038). None of the test results were associated with clinical characteristics.
CONCLUSIONS: In addition to the classic booster effect, TST conversions in patients using MTX can occur due to an increase in IFN-γ. However, it is not possible to exclude true TST conversions. Therefore, other diagnostic methods, like IGRA or chest tomography, should be used when the TST has intermediate results.

Introduction

Nearly 3% of the total population may exhibit psoriasis during their lives [1]. This is an immune-mediated T helper (Th) 17, Th22, and tumor necrosis factor-alpha (TNF-α) disease with systemic and cutaneous inflammatory repercussions [2]. There is an extreme spectrum of severity, with the more severe cases requiring systemic immunosuppressive therapy [3]. The commonly used treatment options are methotrexate (MTX), ciclosporin, and, more recently, TNF-α inhibitors and interleukin (IL) inhibitors [3].

MTX is a dihydrofolate reductase inhibitor that prevents folic acid activation, limits DNA formation and cellular division, and has cytotoxic effects, leading to cell death by apoptosis [4, 5]. MTX is a consolidated and highly available option for treating psoriasis, reducing the number of keratinocytes in plaques of psoriasis, and decreasing inflammation [6]. However, the precise underlying mechanism of action of MTX in psoriasis is not clearly understood [4, 5].

Treatment with biological drugs, especially TNF-α inhibitors, increases the risk of reactivating latent tuberculosis infection (LTBI) in psoriasis patients [7]. Psoriasis patients often have several comorbidities, such as diabetes and obesity, which could increase the risk of LTBI [8]. Therefore, they must be screened for LTBI before the use of immunobiological medications [7, 9]. However, this task proves to be extremely challenging because there is no gold standard test for LTBI. Many factors, such as vaccination, age, and migratory status, make obtaining the correct diagnosis even more difficult, especially in endemic TB areas [10-14].

Another barrier to LTBI diagnosis is determining the correct timing of testing [9]. Increased cytokine expression in psoriasis may cause incorrect screening test results if the test is performed before immunosuppressive therapy [10]. However, numerous psoriasis patients have already started treatment with an immunosuppressor such as MTX when they are referred for LTBI testing, which can alter the test results [9, 10].

To date, no prospective study has addressed the role of MTX therapy on tuberculin skin test (TST) or interferon-gamma release assay (IGRA) results among psoriasis patients living in TB-endemic areas [10-15]. Data on the relationship between cytokines of the Th1 pathway, the inflammatory rates, the clinical characteristics, and the results of the screening tests are also missing [10-15].

Therefore, this study aimed to investigate whether 12-week MTX use can modify the results and the agreement of the TST test and IGRA assays (QuantiFERON-TB Gold) in systemic treatment-naive psoriasis patients vaccinated with the bacillus Calmette-Guérin (BCG) vaccine who were born and lived in a TB-endemic region. Additionally, the study also explored associations of the TB screening tests with clinical and inflammatory factors.

Materials and methods

Study design

This study was a prospective, quasi-experimental, single-arm, self-controlled study associated with a cohort. The study period was between April 2015 and February 2018. The inclusion period was between April 2015 and August 2016. All patients were followed for a minimum period of 18 months after inclusion. After the end of the study, the patients continued the follow-up in the outpatient dermatology clinics.

Ethics statement

The study was approved by the ethics committee of the Federal University of Pernambuco with trial number 42859015.0.0000.5208-CAAE on 01/04/2015. The trial was registered at http://www.ensaiosclinicos.gov.br/rg/RBR-2mt78b/. The study was registered after the enrolment of the patients because the site allows registration before or after the inclusion of participants according to the protocol approved by the ethics committee. The study followed the principles of the Declaration of Helsinki. The patients were included after signing the consent form. The authors confirm that all ongoing and related trials for this drug/intervention are registered.

Sample and eligibility criteria

The inclusion criteria called for patients over 18 years of age, with moderate to severe plaque psoriasis, living in the northeast region of Brazil, referred by dermatologists to initiate the follow-up in the Dermatology Clinic of the Federal University of Pernambuco.

The exclusion criteria were the absence of a BCG vaccination scar, pregnant women, breastfeeding women, previous use of systemic treatment for psoriasis, previous use of immunosuppressants, use of topical medications for psoriasis in the last 6 months, use of drugs aggravating psoriasis, personal history or signs or symptoms of TB, chest X-ray compatible with lung disease other than LTBI, previous malignancy, positive serology for HIV, hepatitis B or C, liver enzyme elevation, renal function impairment, anemia, lymphopenia (< 1500 lymphocytes), platelet count < 100,000, or leukopenia < 3500 leukocytes.

The sample size was calculated based on the reduction of the Psoriasis Area and Severity Index (PASI) by MTX treatment for comparing paired differences. To detect an effect size of 0.65 between paired data with a power of 80% and a two-sided significance level of 5%, the necessary sample size for the paired sample T-test was 22 pairs.

Forty-five patients were referred to initiate follow-up during the study period. The patients underwent general laboratory tests in the hospital laboratory before treatment had been initiated, including complete blood count, renal function, liver enzymes, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), a pregnancy test for women, and serology for HIV and hepatitis B and C. Chest radiography was performed and read in the radiology department of the hospital.

Twelve patients were excluded due to laboratory alteration (ten for liver enzyme elevation, two for renal impairment, one for lymphopenia, and one for anemia); one was excluded due to pregnancy, one was excluded due to HIV, and two were excluded due to failure to return the exams. Three stopped taking the medication during the follow-up, and one was excluded due to coagulation of the blood sample. There were no exclusions due to adverse effects. Twenty-five patients completed the research protocol and the 18-month follow-up.

Data collection

The demographic data collected included sex, age in years, disease duration in years, diabetes (use of medication for type 2 diabetes or glycemia > 126 mg/dl), place of residence (urban or rural), and contact with cattle.

All patients were born and lived in a high-risk area for TB. A standardized risk questionnaire was used to evaluate the presence of active TB and other risk factors for LTBI (cough, asthenia, fever, night sweats, anorexia, weight loss, history of drug abuse, previous contact with a carrier of tuberculosis). The patients were examined, and their weight, height, BMI, and PASI were determined.

Laboratory tests

Blood samples were obtained by direct venipuncture by trained staff. For the QuantiFERON-TB Gold test, one milliliter of blood was collected in each of three tubes separately according to the sequence in the manufacturer's instructions (Cellectis, Melbourne, Australia). For the interferon-gamma (IFN-γ) and TNF-α tests, 3 ml of blood was collected in a tube with citrate. Samples were immediately sent to the laboratory, incubated within one hour after collection, and frozen.

After the collection of blood, TST was performed by trained staff using the Mantoux technique. Two units of purified protein derivative (PPD, RT23, Statens Serum Institut, Copenhagen, Denmark) were injected into the anterior surface of the left forearm. The result of TST was recorded in millimeters, and photographs were obtained at 72 hours. On the day of the TST read, the patients were instructed to intake 7.5 mg of MTX twice in a single day for a total of 15 mg per week without dose progression and 5 mg of folic acid per week. MTX treatment was started only after obtaining the result of the first TST.

Patients were advised about the most frequent adverse effects of MTX and the importance of continuing their medication. They were reevaluated for adverse effects 30 days after starting their medication. If adverse effects were noticed earlier, patients were to attend a consultation before the 30-day reevaluation. Patients who discontinued the medication or skipped doses for any reason were excluded.

The same TST protocol was repeated after 12 weeks of MTX use. At the second visit, TST was applied in the right forearm. Afterward, patients were reassessed every 3 months for clinical and laboratory evaluation. They continued to use MTX 15 mg per week until the treatment ceased to elicit a response, the patients presented significant gastrointestinal intolerance, laboratory changes requiring adjustment of the dosage, the route of administration was changed, or the medication was replaced with another.

After the end of the inclusion period, the QuantiFERON-TB Gold test and the cytokine (INVITROGEN, CA, EUA) measurements were analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA) technique with standardized kits according to the manufacturer's instructions. All tests were performed together.

Interpretation of results

The TST results were analyzed in two ways. First, the TST result was determined to be negative (−) when the size was < 5 mm, indeterminate (I) at ≥ 5 to < 10 mm, and positive (+) at ≥ 10 mm. Second, the TST result was determined to be negative when the induration was < 5 mm and positive when it was ≥ 5 mm.

The IGRA results were also analyzed in two ways. The first analysis was conducted according to the manufacturer's instructions for positive (+), negative (−), and indeterminate (I) results. As with the TST, which can have its cutting pointer rated at 5mm, we carried out a second IGRA analysis in which the indeterminate results were considered positive [16, 17].

The limits of detection for cytokines were defined according to the manufacturer’s instructions (INVITROGEN, CA, EUA). The lower limit was 4 pg/ml for IFN-γ and 3.0 pg/ml for TNF-α. Results below the cutoff points were considered equal to zero. Missing data for any variable were set to zero.

Statistical analyses

The statistical analysis was performed using the IBM Statistical Package version 23.0 (IBM Corp., Armonk, NY). The sample demographic and clinic characteristics are presented descriptively through absolute and percentage frequencies. Cohen’s kappa test was used to assess the agreement between each test and between IGRA and TST results before and after treatment. McNemar’s test was used to verify the change in the test results classified into two categories (positive/negative) and in comparisons of tests. The McNemar-Bowker test was used when the results were classified into three categories (positive/negative/indeterminate). For numeric continuous variables, the normality was tested using the Shapiro-Wilk test. To compare the mean of paired continuous variables (PASI, ESR, CRP, TNF-α, and IFN-γ), Student's t-test for paired variables was used for variables with a normal distribution, and the Wilcoxon test for paired data was used for variables with a non-normal distribution. To compare the TST and IGRA results with the means of numerical continuous clinical (age, disease duration, weight, blood glucose, BMI) and inflammatory variables (PASI, ESR, CRP, TNF-α, and IFN-γ), Student's t-test was performed for variables with a normal distribution, and the Mann-Whitney test was used for variables with a non-normal distribution. Statistical significance was defined as a P-value < 0.05. Missing data were excluded from the analysis.

Results

The sample consisted of 14 women and 11 men. The sample baseline characteristics are described in Table 1. No patients developed tuberculosis during the study period. Any adverse effect was observed during the study period.

Table 1

Baseline demographic and clinical characteristics of the patients enrolled in the study.

Characteristic	n	%
	25	100.00
Sex:
Female	14	56.0
Male	11	44.0
Age group (years):
20 to 29	6	24.0
30 to 59	11	44.0
60 to 75	8	32.0
Duration of psoriasis (years):
1 to 2	6	24.0
3 to 9	8	32.0
≥ 10	11	44.0
Diabetes:
Yes	6	24.0
No	19	76.0
Place of residence:
Urban region	23	92.0
Rural region	2	8.0
Contact with cattle:
Yes	4	16.0
No	21	84.0
Previous contact with a carrier of tuberculosis:
Yes	9	36.0
No	16	64.0
Chest X-ray suggestive of LTBI:
Yes	3	12.0
No	22	88.0
Percentage of PASI reduction:
< 50	3	12.0
50 to 75	5	20.0
> 75	17	68.0

PASI, psoriasis area and severity index.

At baseline, five TST results were > 5 mm, and four were > 10 mm. Two IGRA results were positive, and three were indeterminate (Table 2). Five negative TST results converted to positive, and three baseline positive test results increased in size, resulting in 11 TST results > 5 mm and six results > 10 mm at 12 weeks. Three patients (4, 17, and 22) exhibited conversion of negative IGRAs at the same time as TSTs. Three indeterminate IGRA results reverted to negative in the second test, and one was converted to positive. Only four patients had contact with cattle; two were IGRA−/TST− both times (patients 6,14), one patient was TST−/IGRA Indeterminate both times (25), and one patient (17) was negative on both tests the first time but converted to positive on both tests (Table 2).

Table 2

TST and IGRA results before and after 12 weeks of treatment with methotrexate, excluding 12 patients who tested negative both times.

Patient	TST 1	TST 2	IGRA 1	IGRA 2
3	22	22	POSITIVE	POSITIVE
4	0	6	NEGATIVE	INDETERMINATE
5	12	22	NEGATIVE	NEGATIVE
12	5.5	9	NEGATIVE	NEGATIVE
13	11	11	INDETERMINATE	NEGATIVE
16	0	7	NEGATIVE	NEGATIVE
17	0	8	NEGATIVE	POSITIVE
18	22	22	POSITIVE	POSITIVE
22	5	25	NEGATIVE	POSITIVE
25	0	0	INDETERMINATE	INDETERMINATE
26	0	7	NEGATIVE	NEGATIVE
28	0	0	INDETERMINATE	NEGATIVE
29	0	20	INDETERMINATE	NEGATIVE

TST, tuberculin skin test; IGRA, interferon-gamma release assay.

The TST results became significantly positive on the second test in both analyses (P = 0.037/P = 0.032). IGRA results did not show a pattern of change (P = 0.135/1.0). The TST had a greater agreement (Moderate) before and after treatment than the IGRA (Fair), regardless of the number of categories. The kappa value remained in the same range for the IGRA (κ = 0.27/0.34) and TST (κ = 0.57/0.46) whether they were analyzed with 3 or 2 categories. The agreement between the IGRA and TST was the same before and after treatment (κ = 0.34/0.32). There was no difference between the tests before (P = 1.00) or after (0.289) treatment (Table 3).

Table 3

Concordance between tuberculosis screening tests before and after 12 weeks of treatment with methotrexate.

Variable	Observed		Agreement		McNemar test
	n	%	k value	95% CI
Total	25	100
TST/TST 3 categories	20	80.0	0.57	0.27 to 0.87	P = 0.037*
TST/TST 2 categories	18	72	0.46	0.19 to 0.73	P = 0.032*
IGRA/IGRA 3 categories	18	72.0	0.27	0.14 to 0.69	P = 0.135
IGRA/IGRA 2 categories	18	72.0	0.34	-0.03 to 0.71	P = 1.000
TST/IGRA before	19	76.0	0.34	-0.08 to 0.76	P = 1.000
TST/IGRA after	17	68.0	0.32	-0.03 to 0.68	P = 0.289

TST, tuberculin skin test; IGRA, interferon-gamma release assay. TST 3 categories; negative when t < 5 mm, indeterminate at ≥ 5 to < 10 mm, and positive at ≥ 10 mm. TST 2 categories: negative < 5 mm and positive when ≥ 5 mm. IGRA 3 categories: positive, negative, and indeterminate results. IGRA 2 categories: positive (positive and indeterminate results) and negative (negative results).

(*) P < 0.05.

Comparison of the means and medians before and after treatment revealed that CRP levels (P = 0.022) and PASI scores (P < 0.001) decreased significantly after treatment, while the IFN-γ level (P = 0.005) increased. There were missing data for TNF-α and ESR. A decrease in the ESR and an increase in TNF-α were observed after treatment, but these changes were not significant (Table 4).

Table 4

Differences between CRP, ESR, IFN-γ, TNF-α, and PASI before and after 12 weeks of MTX treatment.

Variable	Before	After	P-value
CRP (mg/dl): Median (P25; P75)	0.54 (0.12; 3.00)	0.40 (0.14; 0.90)	P (1) = 0.022 *
ESR (mm): Median (P25; P75)	13.00 (6.25; 22.25)	7.50 (4.00; 12.75)	P (1) = 0.086
IFN-γ (pg/ml): Mean ± SD	15.95 ± 7.89 (12.68)	18.82 ± 9.17 (16.44)	P (2) = 0.005 *
TNF-α (pg/ml): Median (P25; P75)	0.00 (0.00; 1.97)	3.68 (0.16; 6.61)	P (1) = 0.224
PASI: Median (P25; P75)	13.20 (10.30; 18.90)	2.00 (0.95; 4.40)	P (1) < 0.001 *

ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IFN-γ, interferon-gamma; TNF-α, tumor necrosis factor-alpha; PASI, psoriasis area, and severity index.

(*) P < 0.05 (1) Wilcoxon test for paired data. (2) Student’s t-test for paired data.

There was no association between the TST or IGRA results before or after treatment and age, disease duration, weight, BMI, blood glucose, CRP, or absolute PASI (absolute and percentage) before or after treatment (S1–S4 Tables). Before treatment, there was an association between positive IGRA and higher levels of ESR (P = 0.038) (S1 Table). After treatment, there was no longer an association with ESR (P = 0.443) (S3 Table). After treatment, there was a trend toward an IFN-γ increase (P = 0.072) in the TST-positive group (S4 Table).

Discussion

Many studies report a discordance between LTBI screening tests in patients with psoriasis [10-14]. The TST is usually considered to be responsible for this because it would be easily affected by clinical and epidemiological factors than the IGRA, leading to false-positive results. The exception is immunosuppressed and elderly individuals, who can have false-negative tests [10-12]. In this study, a significant number of TSTs showed positive conversions despite the use of MTX. However, the IGRA presented changes that are not significant but should not be ignored. Studies with serial IGRAs showed changes in the test results in many patient profiles, including psoriasis, with the cause not being completely understood, but may be related to a low release of IFN-γ [18-21].

The known factors responsible for the discordant positive TST results are the following: having lived in an endemic area for TB, age, possible cross-reaction with Mycobacterium bovis (M. bovis) [11-14], and BCG vaccination [22-24]. In endemic areas, BCG is administered at birth, and it is not possible to exclude the environmental presence of Mycobacterium tuberculosis (Mtb) [25, 26]. Therefore, it is necessary to study the test results separately in these populations.

A possible relationship between test results and age was not found. BCG vaccine is also the reason why the TST has a higher positivity in patients under 15 years old [22, 23], while there is a possibility of the IGRA exhibiting a decrease in sensitivity in children aged under 2 years [24]. Therefore, only patients older than 18 years were included. The TSTs-negative tests could be more frequent in the elderly due to a loss of this immune response [26]. However, in comparative studies, the results of the TST and IGRA have been similar in the elderly [27, 28], consistent with our results. The number of participants who had previous contact with cattle was low, and the LTBI screening test results were mostly negative, reducing the possibility of a cross-reaction M. bovis with the TST [12, 13].

When it is not possible to identify epidemiological factors to justify the disagreements between the screening tests it is considered the possibility of interference by the inflammatory process of psoriasis [10–15, 29–31]. Psoriasis is a unique disease with cutaneous and systemic immunologic alterations [1, 15], and its relationship to the screening tests can be assessed in many ways, such as by the PASI at the time of the test, disease duration, comorbidities, inflammatory markers such as ESR, CRP, and cytokines of the Th17 and Th1 pathways. The cytokine levels of the Th17 pathway have not yet been evaluated. To date, no association has been found between IGRA or TST outcomes and the PASI [10, 29]. Studies in other populations did not find an association of the tests with diabetes and obesity [8]; neither did this study. The association between the IGRA and ESR before treatment indicates the possibility of interference of some inflammatory or infectious process in this test.

Another possible factor related to the disagreement in test results is immunosuppression [10, 14]. Each drug has a peculiar mechanism of action in modulating the Th1 and Th17 pathways and should be evaluated individually [15]. The most obvious reason is that the immunosuppressive effect of MTX on lymphocytes would increase the number of negative screening tests, as in other conditions such as HIV [13, 14, 32]. Lymphopenia is associated with negative IGRAs and could be induced by MTX [33]. Patients did not have lymphopenia at the time of testing, and there was no increase in negative IGRAs [11, 16, 34].

A significant increase in positive TST results and IFN-γ was observed after MTX treatment. The missing data for TNF-α were probably responsible for the lack of a significant increase in their results. Tavast et al. [11] found an association between immunosuppression and positive TST results, and one multicentric study found high rates of TST positivity during MTX therapy [35]. Experimental studies observed that mononuclear cell death increases IFN-γ and TNF-α due to the cytotoxic effect of MTX [36-38]. These cytokines are responsible for macrophage activation and the containment of Mtb [29]. Following the cutaneous cell death in psoriasis plaques induced by MTX, patients were again exposed to tuberculin and presented a greater capacity to contain the protein, which increased TST. The tendency toward higher levels of IFN-γ in positive TST patients may be related to this fact.

However, not all cases of TSTs conversions can be considered false positives due to the classic booster effect or increased cytokine. Psoriasis patients’ baseline rates of positive TST results as observed in other studies were close to those found in this study (24%) [39, 40], but the conversion rate was lower even when a booster effect was induced in one month (5% versus 20%) [40, 41]. Considering that three IGRA conversions followed TST conversions, it cannot be ruled out that at least these cases were due to true conversions of anergic tests or recent infection by Mtb [34, 41], although no patient developed TB at follow-up. The maintenance of concordance and the absence of difference between tests after treatment suggest that IGRA conversions counteracted the difference in TST conversions.

Some limitations of this study are the lack of an MTX-free control group, chest tomography [42] to improve the diagnosis of LTBI, and cytokine evaluation in skin biopsies to facilitate better correlation with the TST. Studies including larger populations are important to verify the reproducibility of the data.

Conclusions

In this patient population, TST conversions probably occur by an increase in IFN- γ due to the cytotoxic effect of MTX on psoriasis plaques. However, not all positive tests can be considered false-positive due to cytokine increase or to classical booster effect. In psoriasis patients taking MTX, the responsible for screening should evaluate the possibility of using other techniques, such as the IGRA or chest tomography, concurrently with the TST to increase the accuracy of LTBI diagnosis when TST yields intermediate results (5–10 mm).

TREND statement checklist.

(PDF)

Click here for additional data file.

Measures of associations between positive and negative IGRA results and the average values of numerical variables before MTX treatment.

(DOCX)

Click here for additional data file.

Measures of associations between positive and negative TST results and the average values of numerical variables before MTX treatment.

(DOCX)

Click here for additional data file.

Measures of associations between positive and negative IGRA results and the average values of numerical variables after MTX treatment.

(DOCX)

Click here for additional data file.

Measures of associations between positive and negative TST results and the average values of numerical variables after MTX treatment.

(DOCX)

Click here for additional data file.

CONSORT 2010 flow diagram.

(PDF)

Click here for additional data file.

(DOCX)

Click here for additional data file.

31 Jul 2020

Submitted filename: Reviews answer.docx

Click here for additional data file.

15 Sep 2020

PONE-D-20-23955

TST conversions and an increase in systemic interferon-gamma after MTX introduction in psoriasis patients: An interventional study associated with a cohort.

PLOS ONE

Dear Dr. Medeiros,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 30 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Remco PH Peters, MD, PhD, DLSHTM

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for submitting your clinical trial to PLOS ONE and for providing the name of the registry and the registration number. The information in the registry entry suggests that your trial was registered after patient recruitment began. PLOS ONE strongly encourages authors to register all trials before recruiting the first participant in a study.

As per the journal’s editorial policy, please include in the Methods section of your paper:

i) your reasons for your delay in registering this study (after enrolment of participants started);

ii) confirmation that all related trials are registered by stating: “The authors confirm that all ongoing and related trials for this drug/intervention are registered”.

Please also ensure you report the date at which the ethics committee approved the study as well as the complete date range for patient recruitment and follow-up in the Methods section of your manuscript.

3.  Thank you for including your ethics statement: 'This study was a prospective, quasi-experimental, single-arm, self-controlled study associated with a cohort approved by the ethics committee, with trial number 42859015.0.0000.5208-CAAE on 01/04/2015. The authors confirm that all ongoing and related trials for this drug/intervention are registered at http://www.ensaiosclinicos.gov.br/rg/RBR-2mt78b/ by the number RBR-2mt78b. Forty-five patients were referred to initiate follow-up during the study period and signed the consent form.'

a. Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

b. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Immunosuppression is an important cause of the reactivation of LTBI. Although there are no highly specific diagnostic tests for the diagnosis of LTBI, the use of TST and IGRA are surrogate markers. This study provides prospective data to interpret TST/IGRA conversion in patients with psoriasis who are taking MTX. However, the small sample size makes the data difficult to interpret. Given that participants were BCG vaccinated, the significance of TST changes, while IGRA remains unchanged is hard to interpret. Perhaps the results are a result of boosting (although the repeat test is at 90 days)? I appreciate that the authors have acknowledged several of the limitations of the TST however the sample size is very small, making it difficult to interpret further. I can see that there is a sample size calculation, perhaps a bio-statistician is better placed to comment if conclusions can be made based on the calculation and sample size (not sure if this has already been completed?). It does however, seem the authors have addressed some of the concerns of the previous reviewers.

Although reassuring that no one developed TB in the three-month period, it is a very short follow up period.

- Mix of past and present tense e.g. line 172 (there were no exclusions…), line 241, 317

- Line 206 change to “they were advised to attend the consultation….”

- Line 212 remove “they presented”

- Line 234: should missing data be considered zero or not applicable, as this may artificially increase the number of negative test results (or where these tests not considered negative)?

- Line 276: can this be worded more clearly?

- Line 312: ?”report a discordance between…”

- Line 360/1 – sentence structure needs to be changed

- Sometimes the discussion is a little difficult to follow, one final proofread with a focus on structure may help.

Reviewer #2: In the "Discussion" session, the authors did not mention the possibility of "Boosting effect" occurrence. Even though the TST repetition was performed 12 weeks after the first exam, "Boosting effect" could had happened.

Reference: Cauthen GM, Snider DE Jr, Onorato IM. Boosting of tuberculin sensitivity among Southeast Asian refugees. Am J Respir Crit Care Med. 1994;149(6):1597-1600. doi:10.1164/ajrccm.149.6.8004319

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

18 Oct 2020

Response to Reviewers

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

Answer: I corrected the topics according to the Plos one formatting

2. Thank you for submitting your clinical trial to PLOS ONE and for providing the name of the registry and the registration number. The information in the registry entry suggests that your trial was registered after patient recruitment began. PLOS ONE strongly encourages authors to register all trials before recruiting the first participant in a study.

As per the journal’s editorial policy, please include in the Methods section of your paper:

i) your reasons for your delay in registering this study (after enrolment of participants started);

ii) confirmation that all related trials are registered by stating: “The authors confirm that all ongoing and related trials for this drug/intervention are registered”.

Please also ensure you report the date at which the ethics committee approved the study as well as the complete date range for patient recruitment and follow-up in the Methods section of your manuscript.

Answer:

i) I added the justification in the text

ii) I confirmed that all related trials are registered

3. Thank you for including your ethics statement: 'This study was a prospective, quasi-experimental, single-arm, self-controlled study associated with a cohort approved by the ethics committee, with trial number 42859015.0.0000.5208-CAAE on 01/04/2015. The authors confirm that all ongoing and related trials for this drug/intervention are registered at http://www.ensaiosclinicos.gov.br/rg/RBR-2mt78b/ by the number RBR-2mt78b. Forty-five patients were referred to initiate follow-up during the study period and signed the consent form.'

a. Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

b. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

Answer:

a) I added the name of the ethical committee

b) The ethic statement was added to the field of the submission

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

Answer: All the ethics were included in a separate part of “Ethical statements” and were removed from the text.

Responses to Questions

Reviewer #1: Immunosuppression is an important cause of the reactivation of LTBI. Although there are no highly specific diagnostic tests for the diagnosis of LTBI, the use of TST and IGRA are surrogate markers. This study provides prospective data to interpret TST/IGRA conversion in patients with psoriasis who are taking MTX. However, the small sample size makes the data difficult to interpret. Given that participants were BCG vaccinated, the significance of TST changes, while IGRA remains unchanged is hard to interpret. Perhaps the results are a result of boosting (although the repeat test is at 90 days)? I appreciate that the authors have acknowledged several of the limitations of the TST however the sample size is very small, making it difficult to interpret further. I can see that there is a sample size calculation, perhaps a bio-statistician is better placed to comment if conclusions can be made based on the calculation and sample size (not sure if this has already been completed?). It does, however, seem the authors have addressed some of the concerns of the previous reviewers.

Although reassuring that no one developed TB in the three months, it is a very short follow up period.

Answer :

1) The sample was above the minimum required. Studies with paired variables require a smaller sample. At the end of the text, it is written that it is necessary to repeat the research to verify the reproducibility of the results, preferably in larger samples.

2) The follow-up was 18 months for each participant. This is in the methods section line 118-119.

3) Thank you for your consideration. When I wrote false-positive tests, I included the booster effect. The increase in TST size in MTX psoriasis patients was found in other studies in countries with less environmental exposition to Mycobacterium tuberculosis. Psoriasis patients who undergoing re-testing in one month, have 5% conversions (1); Course the booster effect can occur in three months, but it does not explain everything. There would be three possibilities, the classic booster for the repetition of the TST, the increase of the identification for the increase of the INF gamma and TNF-alfa, and some cases of possible true conversions. IGRA would try to identify these true conversions. The best way to evaluate the booster effect was a control group without treatment. It is placed as a limitation. The text was not very clear about this. I make the text more clear and cited the booster effect.

(1) Ribera M, Zulaica A, Pujol C, et al. Estimation of the prevalence of latent tuberculosis infection in patients with moderate to severe plaque psoriasis in Spain: The Latent study. Actas Dermosifiliogr. 2015;106(10):823-829. DOI:10.1016/j.ad.2015.08.001

- Mix of past and present tense e.g. line 172 (there were no exclusions…), line 241, 317

Thank you for the warning, CORRECTED. English was again revised by experts.

- Line 206 change to “they were advised to attend the consultation….” - CHANGED

- Line 212 remove “they presented” - REMOVED

- Line 234: should missing data be considered zero or not applicable, as this may artificially increase the number of negative test results (or where these tests not considered negative)?

ANSWER: Plos requests to be declared how the missing values were handled. Statistically, the missing data can be filled with values close to mean, estimated values (regression imputation), last observation made found, maximum probability, filled with zero / negative and others possibilitys (1) . Considering them equal to zero reduced our associations. However, there were no missing data for IGRA or TST. We only had for TNF-α and ESR for lack of material in the laboratory in the second test (Line 299). This was probably the reason why TNF-α increased without significance. This may be the reason for the loss of association between IGRA and ESR in the second test, but this discussion would be very hypothetical.

(1) Kang H. The prevention and handling of the missing data. Korean J Anesthesiol. 2013;64(5):402-406. doi:10.4097/kjae.2013.64.5.402

- Line 276: can this be worded more clearly? ANSWER: I tried to make it clear

- Line 312: ?” report a discordance between…” CHANGED

- Line 360/1 – sentence structure needs to be changed - CHANGED

- Sometimes the discussion is a little difficult to follow, one final proofread with a focus on the structure may help.

ANSWER

1) The sequence is: IGRA/TST discordance � epidemiological/ clinical factors � Inflammatory process of psoriasis � Influence of immunosuppression � increase in INF-gamma and TNF-alfa/ cytotoxicity as a partial explanation for changes in TST� discussion about being false ou true positives according to IGRA agreement

2) I changed the words always using “disagreement” to mark the concept in this the discussion as you suggested above

3) I made a change in the structure of the paragraph about the cytotoxic effect of MTX to improve text fluency

4) I added the discussion about the booster effect.

Reviewer #2: In the "Discussion" session, the authors did not mention the possibility of "Boosting effect" occurrence. Even though the TST repetition was performed 12 weeks after the first exam, the "Boosting effect" could have happened.

Reference: Cauthen GM, Snider DE Jr, Onorato IM. Boosting of tuberculin sensitivity among Southeast Asian refugees. Am J Respir Crit Care Med. 1994;149(6):1597-1600. DOI:10.1164/ajrccm.149.6.8004319

ANSWER: Thank you for your consideration. When I speak about false positives I include the booster effect. The increase in TST size in MTX psoriasis patients was found in other studies in countries with less environmental exposition to Mycobacterium tuberculosis. Psoriasis patients who undergoing re-testing in one month, have 5% conversions (1); Course the booster effect can occur in three months, but it does not explain everything. There would be three possibilities, the classic booster for the repetition of the TST, the increase of the identification for the increase of the INF gamma and TNF-alfa, and some cases of possible true conversions. IGRA would try to identify these true conversions. The best way to evaluate the booster effect was a control group without treatment. I tried to improve the text.

(1) Ribera M, Zulaica A, Pujol C, et al. Estimation of the prevalence of latent tuberculosis infection in patients with moderate to severe plaque psoriasis in Spain: The Latent study. Actas Dermosifiliogr. 2015;106(10):823-829. DOI:10.1016/j.ad.2015.08.001

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

27 Oct 2020

TST  conversions and systemic interferon-gamma increase after methotrexate introduction in psoriasis patients

PONE-D-20-23955R1

Dear Dr. Medeiros,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Remco PH Peters, MD, PhD, DLSHTM

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Please respond to Reviewer 3's suggestions:

Reviewer 3:

A single arm, self-controlled study was conducted to determine if the results of the tuberculin skin test (TST) or interferon-gamma release assay in psoriasis patients change after 12 weeks of methotrexate treatment. Clinical and inflammatory markers were also investigated. The proportion of positive TST cases significantly increased at post-treatment. Additionally, serum IFN-γ increased at post-treatment.

Minor revisions:

1-  Line 132: Indicate the statistical testing method which achieves 80% power.

2-  Line 212: Indicate the specific type of Wilcoxon test, as there are at least two.

3- Indicate if any adverse events were observed during the course of the study.

Reviewers' comments:

25 Nov 2020

PONE-D-20-23955R1

TST conversions and systemic interferon-gamma increase after methotrexate introduction in psoriasis patients

Dear Dr. de Medeiros:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof Remco PH Peters

Academic Editor

PLOS ONE